Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2006 3
2007 2
2008 4
2009 4
2010 7
2011 5
2012 7
2013 4
2014 2
2015 2
2016 4
2017 4
2018 3
2019 2
2020 2
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Bomben R, Rossi FM, Vit F, Bittolo T, Zucchetto A, Papotti R, Tissino E, Pozzo F, Degan M, Polesel J, Bulian P, Marasca R, Reda G, Laurenti L, Olivieri J, Chiarenza A, Laureana R, Postorino M, Del Principe MI, Cuneo A, Gentile M, Morabito F, Fronza G, Tafuri A, Zaja F, Foà R, Di Raimondo F, Del Poeta G, Gattei V. Bomben R, et al. Among authors: bulian p. Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18. Leukemia. 2023. PMID: 36807650 Free PMC article. No abstract available.
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Forestieri G, Terzi di Bergamo L, Deodato M, Frustaci AM, Moia R, Deambrogi C, Rasi S, Autore F, Merli M, Mattarucchi R, Fahrni G, Scarfo' L, Gussetti D, Bulian P, Zanatta A, Spina V, Bruscaggin A, Pini K, Piffaretti D, Pirosa MC, Salehi M, Marques de Almeida J, Passweg J, Cavalli F, Zucca E, Gerber B, Stussi G, Gattei V, Ghia P, Gregor M, Passamonti F, Laurenti L, Gaidano G, Tedeschi A, Rossi D, Condoluci A. Forestieri G, et al. Among authors: bulian p. Hematol Oncol. 2022 Dec;40(5):1100-1104. doi: 10.1002/hon.3032. Epub 2022 Jun 1. Hematol Oncol. 2022. PMID: 35613703 No abstract available.
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.
Bomben R, Rossi FM, Vit F, Bittolo T, D'Agaro T, Zucchetto A, Tissino E, Pozzo F, Vendramini E, Degan M, Zaina E, Cattarossi I, Varaschin P, Nanni P, Berton M, Braida A, Polesel J, Cohen JA, Santinelli E, Biagi A, Gentile M, Morabito F, Fronza G, Pozzato G, D'Arena G, Olivieri J, Bulian P, Pepper C, Hockaday A, Schuh A, Hillmen P, Rossi D, Chiarenza A, Zaja F, Di Raimondo F, Del Poeta G, Gattei V. Bomben R, et al. Among authors: bulian p. Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20. Clin Cancer Res. 2021. PMID: 34285062
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Pepper AGS, Zucchetto A, Norris K, Tissino E, Polesel J, Soe Z, Allsup D, Hockaday A, Ow PL, Hillmen P, Rawstron A, Catovsky D, Bulian P, Bomben R, Baird DM, Fegan CD, Gattei V, Pepper C. Pepper AGS, et al. Among authors: bulian p. Leukemia. 2022 Jan;36(1):271-274. doi: 10.1038/s41375-021-01322-1. Epub 2021 Jun 19. Leukemia. 2022. PMID: 34148055 Free PMC article. No abstract available.
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
Minard-Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, Delgado RF, Alexander S, Uyttebroeck A, Bollard CM, Zsiros J, Csoka M, Kazanowska B, Chiang AK, Miles RR, Wotherspoon A, Adamson PC, Vassal G, Patte C, Gross TG; European Intergroup for Childhood Non-Hodgkin Lymphoma; Children’s Oncology Group. Minard-Colin V, et al. N Engl J Med. 2020 Jun 4;382(23):2207-2219. doi: 10.1056/NEJMoa1915315. N Engl J Med. 2020. PMID: 32492302 Free PMC article. Clinical Trial.
A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma.
Lovisa F, Binatti A, Coppe A, Primerano S, Carraro E, Pillon M, Pizzi M, Guzzardo V, Buffardi S, Porta F, Farruggia P, De Santis R, Bulian P, Basso G, Lazzari E, d'Amore ESG, Bortoluzzi S, Mussolin L. Lovisa F, et al. Among authors: bulian p. Haematologica. 2019 Sep;104(9):e406-e409. doi: 10.3324/haematol.2018.211631. Epub 2019 Feb 28. Haematologica. 2019. PMID: 30819919 Free PMC article. No abstract available.
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Bo MD, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R. D'Agaro T, et al. Among authors: bulian p. Haematologica. 2019 Sep;104(9):e410-e414. doi: 10.3324/haematol.2018.212811. Epub 2019 Feb 28. Haematologica. 2019. PMID: 30819916 Free PMC article. No abstract available.
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A. Tissino E, et al. Among authors: bulian p. J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4. J Exp Med. 2018. PMID: 29301866 Free PMC article.
51 results